Compare Vanguard Mega Cap Growth ETF (MGK) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Vanguard Mega Cap Growth ETF trades at $91.14 (market cap $33.70B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Vanguard Mega Cap Growth ETF is far larger — about 4.5× Spyre Therapeutics Inc. Common Stock's market cap, and Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Mega Cap Growth ETF for 45 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MGK | SYRE | |
|---|---|---|
Market Cap | $33.70B | $7.52B |
Volume | 775,002 | 1,441,031 |
Sector | Broad Market / Factor | Health |
52-Week High | $95.11 | $108.92 |
52-Week Low | $70.70 | $22.18 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK, the Vanguard Mega Cap Growth ETF, trades at $94.19, up 0.12% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF, tracking large-cap U.S. growth stocks like Nvidia and Apple, lacks disclosed fundamental ratios but benefits from a low 0.05% expense ratio and recent positive media coverage highlighting its long-term growth potential and tech concentration.
The outlook for MGK is favorable for growth-oriented investors, driven by its focus on mega-cap tech leaders, though concentration risk and market volatility pose challenges. Analyst sentiment is broadly positive, with the ETF positioned to capitalize on sustained growth trends, but investors should weigh its reliance on top holdings against diversification needs.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
